Brian Halak
Partner @ Domain Associates
Philadelphia, United States
Brian Halak is a Series B investor at Domain Associates in Philadelphia focused on Biotechnology and Health Care. Brian Halak is based out of Wayne, Pennsylvania and is the Partner at Domain Associates and Board of Director at Ladder Bio (formerly ThirdLaw Molecular). Brian previously served as the Founder and CEO at Nobias Therapeutics. Brian Halak attended the University of Pennsylvania.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 11%
Last updated:
For AI agents: llms.txt
Industries Brian Halak invests in
Stages Brian Halak invests in
Countries Brian Halak invests in
Investment Focus
Industry
- Biotechnology 8 (44%)
- Health Care 6 (33%)
- Medical 5 (28%)
- Genetics 3 (17%)
- Biopharma 2 (11%)
Stage
- Series B 6 (33%)
- Series C 4 (22%)
- Series A 1 (6%)
- Series D 1 (6%)
- Post-IPO Debt 1 (6%)
Country
- United States 8 (44%)
- Hong Kong 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SonoThera
|
SonoThera is a biotechnology company that creates non-viral genetic therapies using ultrasound. Its mission is to develop genetic medicines that treat the root cause of human disease. SonoThera is expanding the possibilities of disease treatment with ultrasound-guided nonviral gene therapy for diseases with suboptimal or non-existent treatments. Itaims to improve the lives and health of millions of people. | $125M / Series B / Jun 10, 2026 | |
|
SonoThera
|
SonoThera is a biotechnology company that creates non-viral genetic therapies using ultrasound. Its mission is to develop genetic medicines that treat the root cause of human disease. SonoThera is expanding the possibilities of disease treatment with ultrasound-guided nonviral gene therapy for diseases with suboptimal or non-existent treatments. Itaims to improve the lives and health of millions of people. | $60.8M / Series A / Dec 05, 2022 | |
Immunitas Therapeutics
|
Immunitas is unlocking human immunology using novel single cell analyses to develop targeted therapeutics for patients with challenging, complex cancers. Translating findings from laboratory research to meaningful clinical advances in humans is a longstanding challenge in the oncology field. Immunitas was founded to directly address this problemand unlock a variety of novel drug targets based on discovery rooted in human biology. They are pursuing this goal with a team of pioneers in these areas across their scientific founders, management, and investors.At Immunitas, they employ a single cell sequencing platform to dissect the biology of immune cells in human tumors. Their focus on human samples allows us to start with and stay closer to the most relevant and translatable biology for patients and accelerates the pace of their research. They are identifying novel, exciting oncology targets and, importantly, developing key biomarkers to guide the selection of patients who may benefit from their new drugs. They are leveraging expertise in antibody discovery and engineering to create powerful therapies that modulate these targets, and are currently advancing a number of programs toward early human studies. | $58M / Series B / Aug 18, 2021 | |
Dicerna Pharmaceuticals
|
Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The productcandidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others.The company was founded in 2007 and is headquartered in Lexington, Massachusetts. | $70M / Post-IPO Debt / Mar 30, 2017 | |
Bionano Genomics
|
Bionano Genomics is a biotechnology company that specializes in genome mapping and analysis. The company develops and markets the Saphyr system, which is a platform for ultra-sensitive and ultra-specific structural variation detection in DNA. Structural variations are alterations in the DNA structure, such as insertions, deletions, inversions, andtranslocations, that can be associated with various genetic disorders and diseases, including cancer.Bionano Genomics' Saphyr system uses a technology called optical genome mapping (OGM) to analyze long DNA molecules. OGM allows for the direct visualization and analysis of structural variations in the genome without the need for sequencing. This technology can provide valuable insights into the structural variations in an individual's genome, which can be important for understanding disease mechanisms, and genetic disorders, and for guiding personalized treatment strategies. | $31.7M / Series D / Aug 01, 2016 | |
Kona Medical
|
Kona Medical is committed to alleviating the suffering and health risks associated with drug-resistant hypertension with a more effective, less invasive approach to renal artery denervation. The company was founded in 2009 by Michael Gertner, MD, with seed financing from Essex Woodlands. Kona was formed on the basis of combining Dr. Gertner’sinventions in the field with the assets of Therus Corporation, a predecessor company in the field of therapeutic focused ultrasound. | Debt Financing / Sep 02, 2015 | |
|
Bionano Genomics
|
Bionano Genomics is a biotechnology company that specializes in genome mapping and analysis. The company develops and markets the Saphyr system, which is a platform for ultra-sensitive and ultra-specific structural variation detection in DNA. Structural variations are alterations in the DNA structure, such as insertions, deletions, inversions, andtranslocations, that can be associated with various genetic disorders and diseases, including cancer.Bionano Genomics' Saphyr system uses a technology called optical genome mapping (OGM) to analyze long DNA molecules. OGM allows for the direct visualization and analysis of structural variations in the genome without the need for sequencing. This technology can provide valuable insights into the structural variations in an individual's genome, which can be important for understanding disease mechanisms, and genetic disorders, and for guiding personalized treatment strategies. | $53M / Series C / Nov 20, 2014 | |
|
Bionano Genomics
|
Bionano Genomics is a biotechnology company that specializes in genome mapping and analysis. The company develops and markets the Saphyr system, which is a platform for ultra-sensitive and ultra-specific structural variation detection in DNA. Structural variations are alterations in the DNA structure, such as insertions, deletions, inversions, andtranslocations, that can be associated with various genetic disorders and diseases, including cancer.Bionano Genomics' Saphyr system uses a technology called optical genome mapping (OGM) to analyze long DNA molecules. OGM allows for the direct visualization and analysis of structural variations in the genome without the need for sequencing. This technology can provide valuable insights into the structural variations in an individual's genome, which can be important for understanding disease mechanisms, and genetic disorders, and for guiding personalized treatment strategies. | $10M / Series C / Oct 02, 2013 | |
|
Dicerna Pharmaceuticals
|
Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The productcandidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others.The company was founded in 2007 and is headquartered in Lexington, Massachusetts. | Series C / Jul 31, 2013 | |
|
Kona Medical
|
Kona Medical is committed to alleviating the suffering and health risks associated with drug-resistant hypertension with a more effective, less invasive approach to renal artery denervation. The company was founded in 2009 by Michael Gertner, MD, with seed financing from Essex Woodlands. Kona was formed on the basis of combining Dr. Gertner’sinventions in the field with the assets of Therus Corporation, a predecessor company in the field of therapeutic focused ultrasound. | $10M / Series C / Dec 04, 2012 | |
| See all 18 investments → | |||
Co-Investors
About Domain Associates
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA.Domain’s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices,while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics. The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 200 life-sciences companies. The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field.
Domain Associates Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Brian Dovey
Partner
|
|||
|
Brian Halak
Partner
|
|||
Dennis Podlesak
Venture Capitalist
|
|||
Eckard Weber
Partner
|
|||
Jesse I. Treu
Founding Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Brian Halak invest in?
Brian Halak invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Brian Halak last invest?
The most recent investment recorded for Brian Halak closed in Jun 2026. Shizune tracks 18 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
